Overview

This trial is active, not recruiting.

Condition human immunodeficiency virus
Sponsor Johns Hopkins University
Collaborator National Institutes of Health (NIH)
Start date January 2005
Trial size 101 participants
Trial identifier NCT00244803, 03-07-02-01

Summary

The purpose of this study is to learn whether HIV-infected patients have blood abnormalities which could lead to heart attack or stroke, and to find out what factors may contribute to these abnormalities.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model defined population
Time perspective longitudinal

Eligibility Criteria

Male or female participants from 18 years up to 65 years old.

Inclusion Criteria:18-65 years old, previous FRAM 1 participant, HIV positive - Exclusion Criteria:Artificial knee or hip replacement or Harrington rod.Metal objects in the body.Pregnancy. Breastfeeding or less than 3 months after breastfeeding.Weight more than 300 pounds.On insulin, pancreatic enzymes, or thioridazine. -

Additional Information

Official title Redistribution and Metabolic Change in HIV Infection: Protocol 2 (FRAM Fat 2)
Principal investigator Joseph Cofrancesco Jr., M.D.
Description This research is being done to learn whether HIV-infected patients have abnormalities in their blood vessels that could eventually lead to heart attack or stroke (atherosclerosis), in how fat is distributed in their body and in how their body handles fat and sugars. If there are abnormalities, this study will also try to find out what factors may contribute to those abnormalitites. People who participated in FRAM 1 may join FRAM 2.
Trial information was received from ClinicalTrials.gov and was last updated in October 2005.
Information provided to ClinicalTrials.gov by Johns Hopkins University.